Literature DB >> 8363282

Specific RNA drug therapy of hepatitis viruses.

W A Carter1, R J Suhadolnik, W E Müller, B E Korba, H R Hubbell, G Garcia, D R Strayer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8363282      PMCID： PMC7167895          DOI： 10.1111/j.1749-6632.1993.tb35938.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  6 in total

1.  A cell culture assay for compounds which inhibit hepatitis B virus replication.

Authors:  B E Korba; G Milman
Journal:  Antiviral Res       Date:  1991 Mar-Apr       Impact factor: 5.970

2.  2',5'-oligoadenylates inhibit relaxation of supercoiled DNA by calf thymus DNA topoisomerase I.

Authors:  F J Castora; C E Erickson; T Kovács; K Lesiak; P F Torrence
Journal:  J Interferon Res       Date:  1991-06

3.  Topoisomerase I-mediated integration of hepadnavirus DNA in vitro.

Authors:  H P Wang; C E Rogler
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

4.  8-Azido double-stranded RNA photoaffinity probes. Enzymatic synthesis, characterization, and biological properties of poly(I,8-azidoI).poly(C) and poly(I,8-azidoI).poly(C12U) with 2',5'-oligoadenylate synthetase and protein kinase.

Authors:  S W Li; J J Moskow; R J Suhadolnik
Journal:  J Biol Chem       Date:  1990-04-05       Impact factor: 5.157

5.  Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1982-06-25       Impact factor: 17.586

6.  Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions.

Authors:  M A Sells; A Z Zelent; M Shvartsman; G Acs
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.